Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • ASSOCIATION  (7)
  • 1
    Keywords: CANCER ; BLOOD ; CELL-PROLIFERATION ; MODEL ; COHORT ; DISEASE ; RISK ; tumour ; ASSOCIATION ; PROGRESSION ; resistance ; PLASMA ; AGE ; MEN ; PROSPECTIVE COHORT ; prostate cancer ; PROSTATE-CANCER ; SWEDEN ; HIGH-LEVEL ; leptin ; insulin ; IGF-I ; ONCOLOGY ; REGRESSION ; RADICAL PROSTATECTOMY ; development ; GROWTH-FACTOR-I ; LEVEL ; case control studies ; INTERVAL ; INSULIN-RESISTANCE ; BODY-MASS INDEX ; USA ; prospective ; prospective study ; STEROID-HORMONES ; odds ratio ; C-PEPTIDE ; ANDROGEN ; prostatic neoplasms ; LOGISTIC-REGRESSION ; GENERAL-POPULATION ; insulin resistance ; FASTING GLUCOSE ; TYPE-2 DIABETES-MELLITUS ; blood glucose ; META-REGRESSION ANALYSIS ; SERUM LEPTIN LEVELS
    Abstract: Factors related to insulin resistance have been implicated in prostate cancer development, however, few analytical studies support such an association. We performed a case control study on 392 prostate cancer cases and 392 matched controls nested in a prospective cohort in Northern Sweden. Plasma concentrations of C-peptide, leptin, glycated haemoglobin (HbA1c) and fasting and post-load glucose were analysed and homeostatic model assessment of insulin resistance (HOMA-IR) was calculated. Conditional logistic regression analyses were used to calculate odds ratios (OR) of prostate cancer. High levels of C-peptide, HOMA-IR, leptin and HbA1c were associated with significant decreases in risk of prostate cancer, with ORs for top vs. bottom quartile for C-peptide of 0.59 (95% Confidence Interval [CI], 0.40-0.89; p(trend) = 0.008), HOMA-IR 0.60 (95% CI, 0.38-0.94; p(trend) = 0.03), leptin 0.55 (95% CI, 0.36-0.84; p(trend) = 0.006) and HbA1c 0.56 (95% CI, 0.35-0.91; p(trend) = 0.02). All studied factors were strongly inversely related to risk among men less than 59 years of age at blood sampling, but not among older men, with a significant heterogeneity between the groups for leptin (p(heterogeneity) = 0.006) and fasting glucose (p(heterogeneity) = 0.03). C-peptide and HOMA-IR were strongly inversely related to non-aggressive cancer but were non-significantly positively related to risk of aggressive disease (p(heterogeneity) = 0.007 and 0.01, respectively). Our data suggest that androgens, which are inversely associated with insulin resistance, are important in the early prostate cancer development, whereas insulin resistance related factors may be important for tumour progression. (c) 2007 Wiley-Liss, Inc
    Type of Publication: Journal article published
    PubMed ID: 17278097
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CANCER ; tumor ; PROSTATE ; COHORT ; EPIDEMIOLOGY ; RISK ; METABOLISM ; TUMORS ; BINDING ; ASSOCIATION ; NO ; hormone ; PLASMA ; prostate cancer ; PROSTATE-CANCER ; SWEDEN ; cancer risk ; case-control studies ; HIGH-LEVEL ; SERUM ; case control study ; case-control study ; ASSOCIATIONS ; INCREASE ; TUMORIGENESIS ; RADICAL PROSTATECTOMY ; prospective studies ; LEVEL ; case control studies ; methods ; PLASMA-LEVELS ; USA ; HORMONES ; TESTOSTERONE ; prospective ; prospective study ; STEROID-HORMONES ; odds ratio ; CANCER-RISK ; CIRCULATING LEVELS ; ANDROGEN ; prostatic neoplasms ; androgens ; ENDOGENOUS SEX-HORMONES ; ANDROSTANEDIOL GLUCURONIDE ; FREE TESTOSTERONE ; PLASMA TESTOSTERONE
    Abstract: BACKGROUND. Androgens have been implicated in prostate tumorigenesis, but prospective studies have overall reported no association between circulating levels of androgens and risk of prostate cancer. However, some recent studies have shown that a high level of testosterone increase the risk of non-aggressive tumors but is associated with a decreased risk of aggressive tumors. METHODS. We prospectively measured plasma levels of total testosterone, androstanediol glucuronide (A-diol-g) and sex hormone binding globuline (SHBG) and calculated estimated levels of free testosterone, in a nested case-control study of 392 cases and 392 matched controls. RESULTS. None of the studied hormones were significantly associated with prostate cancer risk in the full study group or in subgroups according to tumor aggressiveness. Odds ratios in the full study group, for top versus bottom quartile, was for total testosterone 1.25 (95% Cl = 0.79-2.00; P-trend = 0.51); free testosterone, 1.31 (95% Cl = 0.82-2.07; P-trend = 0.35); A-diol-g, 0.88 (95% Cl = 0.59-1.33; P-trend = 0.77); and for SHBG, 1.01 (95% Cl = 0.64-1.58; P-trend = 0.94). CONCLUSIONS. We found no significant associations between androgen levels and risk of prostate cancer in this population-based, non-screened cohort. Prostate 67: 1230-1237, 2007. (c) 2007 Wiley-Liss, Inc
    Type of Publication: Journal article published
    PubMed ID: 17562541
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: CANCER ; DIAGNOSIS ; COHORT ; RISK ; ASSOCIATION ; breast cancer ; BREAST-CANCER ; WOMEN ; OBESITY ; SWEDEN ; POSTMENOPAUSAL WOMEN ; leptin ; IGF-I ; case-control study ; WEIGHT ; GROWTH-FACTOR-I ; OVERWEIGHT ; prospective ; C-PEPTIDE ; SERUM ADIPONECTIN ; Adiponectin ; NORTHERN SWEDEN ; GLUCOSE-HOMEOSTASIS ; Glycated haemoglobin
    Abstract: It is hypothesized that insulin resistance and related metabolic factors may influence breast cancer risk, however the epidemiological evidence remains inconclusive. We conducted a case-control study nested in a prospective cohort in Northern Sweden, to clarify the associations of body mass index (BMI), leptin, adiponectin, C-peptide, and glycated haemoglobin (HbA1c) with breast cancer risk. We also investigated whether these associations may be modified by age at diagnosis, tumour stage, and oestrogen and progesterone receptor status. During follow-up, 561 women developed invasive breast cancer and 561 matched controls were selected. Conditional logistic regression was used to calculate odds ratios (OR) as estimates of relative risk, and 95% confidence intervals (CI). The associations of BMI, leptin and HbA1c with breast cancer risk differed significantly according to whether the tumour was diagnosed as stage I or stage II-IV (P (heterogeneity) all 〈 0.05). These factors were significantly inversely associated with risk in the group of stage I tumours, with ORs for top vs. bottom tertile for BMI of 0.48 (95% CI, 0.30-0.78, P (trend) = 0.004); leptin, 0.64 (95% CI, 0.41-1.00, P (trend) = 0.06); and HbA1c, 0.47 (95% CI, 0.28-0.80, P (trend) = 0.005). For stage II-IV tumours, there was a suggestion of an increased risk with higher levels of these factors. There were no significant differences in the associations of BMI, leptin, adiponectin, C-peptide and HbA1c with breast cancer risk in subgroups of age at diagnosis or tumour receptor status. This prospective study suggests that BMI, leptin and HbA1c influence breast tumour initiation and progression
    Type of Publication: Journal article published
    PubMed ID: 18330696
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: CANCER ; BLOOD ; carcinoma ; COHORT ; cohort studies ; cohort study ; RISK ; ASSOCIATION ; HEALTH ; WOMEN ; OBESITY ; PROSPECTIVE COHORT ; COLORECTAL-CANCER ; SWEDEN ; CARCINOMAS ; body mass index ; REGRESSION ; ASSOCIATIONS ; WEIGHT ; BODY-SIZE ; GROWTH-FACTOR-I ; metabolic syndrome ; blood pressure ; SERUM-LEVELS ; prospective ; CORONARY HEART-DISEASE ; INCREASED RISK ; CANCERS ; CANCER-RISK ; CIRCULATING LEVELS ; C-PEPTIDE ; BODY-MASS ; endometrial neoplasms ; journals ; AGED NORWEGIAN MEN ; metabolic syndrome X
    Abstract: The authors examined the association between the metabolic syndrome and risk of incident endometnal and fatal uterine corpus cancer within a large prospective cohort study Approximately 290,000 women from Austria, Norway, and Sweden were enrolled during 1974-2005, with measurements of height, weight, systolic and diastolic blood pressure, and circulating levels of glucose, total cholesterol, and tnglycendes Relative risks were estimated using Cox proportional hazards regression. The metabolic syndrome was assessed as a composite z score, as the standardized sum of z scores for body mass index, blood pressure, glucose, cholesterol, and tnglycendes. A total of 917 endonnetnal carcinomas and 129 fatal cancers were identified Increased risks of incident endometnal carcinoma and fatal uterine corpus cancer were seen for the metabolic syndrome factors combined, as well as for individual factors (except for cholesterol) The relative risk of endometnal carcinoma for the metabolic syndrome was 1.37 (95% confidence interval 1 28, 1 46) per 1-unit increment of z score The positive associations between metabolic syndrome factors (both individually and combined) and endometrial carcinoma were confined to the heaviest women. The association between the metabolic syndrome and endometnal carcinoma risk seems to go beyond the risk conferred by obesity alone, particularly in women with a high body mass index
    Type of Publication: Journal article published
    PubMed ID: 20219764
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    Keywords: CANCER ; BLOOD ; FOLLOW-UP ; CANCER MORTALITY ; COHORT ; DEATH ; DISEASE ; incidence ; MORTALITY ; RISK ; RISKS ; IMPACT ; RISK-FACTORS ; BIOMARKERS ; ASSOCIATION ; BREAST ; breast cancer ; BREAST-CANCER ; prevention ; HEALTH ; AGE ; WOMEN ; OBESITY ; SWEDEN ; cancer risk ; HYPERTENSION ; PROJECT ; body mass index ; POSTMENOPAUSAL WOMEN ; ONCOLOGY ; REGRESSION ; WEIGHT ; CARDIOVASCULAR-DISEASE ; METAANALYSIS ; biomarker ; methods ; metabolic syndrome ; blood pressure ; CANCER INCIDENCE ; PREMENOPAUSAL ; INCREASED RISK ; CANCER-RISK ; CANCER-MORTALITY ; BODY-MASS ; breast cancer risk ; INTERVENTIONS ; COMPLETENESS ; REGRESSION DILUTION
    Abstract: Background: Few studies have assessed the metabolic syndrome (MetS) as an entity in relation to breast cancer risk, and results have been inconsistent. We aimed to examine the association between MetS factors (individually and combined) and risk of breast cancer incidence and mortality. Methods: Two hundred ninety thousand women from Austria, Norway, and Sweden were enrolled during 1974-2005, with measurements of height, weight, blood pressure, and levels of glucose, cholesterol, and triglycerides. Relative risks (RR) of breast cancer were estimated using Cox proportional hazards regression for each MetS factor in quintiles and for standardized levels (z-scores) and for a composite z-score for the MetS. Results: There were 4,862 incident cases of breast cancer and 633 deaths from breast cancer identified. In women below age 50, there was a decreased risk of incident cancer for the MetS (per 1-unit increment of z-score; RR, 0.83; 95% confidence interval, 0.76-0.90) as well as for the individual factors (except for glucose). The lowest risks were seen among the heaviest women. In women above age 60, there was an increased risk of breast cancer mortality for the MetS (RR, 1.23; 95% confidence interval, 1.04-1.45) and for blood pressure and glucose. The strongest association with mortality was seen for increased glucose concentrations. Conclusions: The MetS was associated with a decreased risk of incident breast cancer in women below age 50 with high body mass index, and with an increased risk of breast cancer mortality in women above 60. Impact: Lifestyle interventions as recommended for cardiovascular disease prevention may be of value to prevent breast cancer mortality in postmenopausal women. Cancer Epidemiol Biomarkers Prev; 19(7); 1737-45. (C) 2010 AACR
    Type of Publication: Journal article published
    PubMed ID: 20615887
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    Keywords: CANCER ; COHORT ; cohort studies ; EPIDEMIOLOGY ; RISK ; ASSOCIATION ; WOMEN ; OBESITY ; cholesterol ; BLOOD-PRESSURE ; ADULTS ; METAANALYSIS ; blood pressure ; BODY-MASS INDEX ; OVERWEIGHT ; colorectal neoplasms ; INDIVIDUAL DATA ; blood glucose ; INSULIN-RESISTANCE SYNDROME ; metabolic syndrome X ; REGRESSION DILUTION ; triglycerides ; VASCULAR MORTALITY
    Abstract: BACKGROUND: The metabolic syndrome (MetS) has been related to an increased risk of colorectal cancer, but the modest size of previous studies precluded detailed characterization of the role of individual MetS factors and their interaction on risk. METHODS: In the Metabolic Syndrome and Cancer Project (Me-Can), data on body mass index (BMI), blood pressure, and blood levels of glucose, cholesterol, and triglycerides were available for 578,700 men and women. The mean age of participants at baseline was 44 years, and the mean follow-up was 12 years. Relative risks (RR) of colorectal cancer per 1 standard deviation increment in Z score of factors and for a combined MetS score, were calculated from Cox regression models, including adjustment for potential confounders. RESULTS: During follow-up, 2834 men and 1861 women were diagnosed with colorectal cancer. The RR of colorectal cancer for the MetS score was 1.25 (95% confidence interval [CI], 1.18-1.32) in men, and 1.14 (95% CI, 1.06-1.22) in women. Significant associations also were observed in men for BMI (RR, 1.07; 95% CI, 1.02-1.13), blood pressure (RR, 1.10; 95% CI, 1.02-1.18), and triglycerides (RR, 1.17; 95% CI, 1.06-1.28) and, in women, for BMI (RR, 1.08; 95% CI, 1.01-1.15). There was no significant positive interaction between the metabolic factors on risk. CONCLUSIONS: The combination of metabolic factors and some separate factors was related to an increased risk of colorectal cancer, but there was no interaction between metabolic factors.
    Type of Publication: Journal article published
    PubMed ID: 21171019
    Signatur Availability
    BibTip Others were also interested in ...
  • 7
    Keywords: CANCER ; FOLLOW-UP ; COHORT ; cohort study ; incidence ; MORTALITY ; ASSOCIATION ; AGE ; ovarian cancer ; WOMEN ; ADULTS ; PHYSICAL-ACTIVITY ; metabolic syndrome ; BODY-MASS INDEX ; SERUM-CHOLESTEROL ; REGRESSION DILUTION ; ANTHROPOMETRIC MEASURES ; CONOR
    Abstract: BACKGROUND: No studies have so far evaluated the impact of the metabolic syndrome (MetS) as an entity on ovarian cancer risk. The authors aimed to examine the association between factors in the MetS, individually and combined, and risk of ovarian cancer incidence and mortality. METHODS: Altogether, 290,000 women from Austria, Norway and Sweden were enrolled during 1974-2005, with measurements taken of height, weight, blood pressure and levels of glucose, cholesterol and triglycerides. Relative risks (RRs) of ovarian cancer were estimated using Cox regression for each MetS factor in quintiles and for standardized levels (z-scores), and for a composite z-score for the MetS. RRs were corrected for random error in measurements. RESULTS: During follow-up, 644 epithelial ovarian cancers and 388 deaths from ovarian cancer were identified. There was no overall association between MetS and ovarian cancer risk. Increasing levels of cholesterol [RR 1.52, 95% confidence interval (95% CI) 1.01-2.29, per 1-U increment of z-score] and blood pressure (RR 1.79, 95% CI 1.12-2.86) conferred, however, increased risks of mucinous and endometrioid tumours, respectively. In women below the age of 50 years, there was increased risk of ovarian cancer mortality for MetS (RR 1.52, 95% CI 1.00-2.30). Increasing levels of BMI (RR 1.17, 95% CI 1.01-1.37) conferred increased risk of ovarian cancer mortality in women above the age of 50 years. CONCLUSION: There was no overall association between MetS and ovarian cancer risk. However, increasing levels of cholesterol and blood pressure increased the risks of mucinous and endometrioid tumours, respectively. Increasing levels of BMI conferred an increased risk of ovarian cancer mortality in women above the age of 50 years.
    Type of Publication: Journal article published
    PubMed ID: 21984693
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...